ESMO 2023 | Phase II trial of nivolumab plus ipilimumab in advanced bladder cancer of variant histologies

Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, discusses a Phase II trial (NCT03333616) which assessed the safety and efficacy of nivolumab plus ipilimumab in patients with advanced bladder cancer of variant histologies (BCVH). A previous trial in 19 patients with BCVH reported an objective response rate (ORR) of 37% with nivolumab plus ipilimumab. This expansion cohort enrolled 49 patients and a similar ORR of 35% was observed, with no new toxicity signals, representing a promising avenue for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.